Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 1 of 40 PageID #: 220
`Case 1:14—cv—O1453—LPS Document 43-1 Filed 10/22/15 Page 1 of 40 Page|D #: 220
`
`
`
`EXHIBIT 1
`
`EXHIBIT 1
`
`
`
`

`
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 2 of 40 PageID #: 221
`Case 1:14-cv—O1453-LPS Document:-4
`/15 Page 2 of 40 Page|D #: 221
`
`ITEE} STATES E} i<1PA}?;TE\/1,§£NT Q37 COMMER{§‘fE
`
`F_.-haited States ?at€-nt and ’E‘mdemark {fiffisse
`
`March (34, 2335
`
`THIS IS T0 CER’"§_‘iEFY 'E‘3%{A'i" ANNEZXEZEE E:¥.ERE"E0 IS A TRUE C{)E""x’ IE'<‘E?;{)?‘/E
`
`’.§.“BI§4? REECGRDS GE‘ TEES QFFICE OF:
`
`FATENT: 8,163,723
`
`ISSUE }}A’}_"§<l: Aprii 24, 2012
`
`By‘ As.1é'hm“i fy mi” the
`Under Seerefary 0f Cammerce fur Xizieiiectuai Flrupcrty
`and i}=1Zrmtmy 9f the United $mtes Patent am? Trademark fiffice:
`
`.
`zijfirz mu ,3/’
`T°gv’=«.,3jmfi
`2 ma: -{xx
`W... ifiaamraazwifizjgy
`{fer fyizag ()fi“:»£er
`
`
`
`
`
`MED_DYM_00018010
`
`

`
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 3 of 40 PageID #: 222
`Case 1:14-cv-01453-LPS Document 43t:§§§§§§§1§1§§§‘§§éRé§%%i§rfi1§§%§§%§§é%llit§§%%§%lD #3 222
`{.3 1 {>3
`
`‘tglaéieé Eétatea fiateiit
`.§_.:’;.§.§:/2 at al.
`
`mm: mt;
`
`
`es s,tea:2a3 ea
`IE}.:«'s,§s~,*. of Eaieiiiz Apia 2&3, .2132
`
`ziczsj;
`
`~'1,6f)"/,022’§
`4,7.l0,4 .
`
`4,861,765
`45/92,474
`479941439
`4.995535
`5 $363,222
`
` >w>>>>>»>>>wm»>>>>>e»w>>>>>>
`
`55362,’/'21
`5,420,120
`5,’08,0.9,”‘
`5,352,545
`5,658,919
`5,707,924
`5,837,599
`62,8-*§91;!e5
`5,889,015
`5,914,122
`5,972,926
`
`559 A
`}
`5,01.
`3
`6,057,307
`a.,.
`,._
`5,19'7;'76‘ B!
`‘6:26L5.3; B}
`
`6,’:
`.153 El
`5319,51: 21
`6,330,938 131
`
`S/l98t3 Sclimirifiia
`12/198'? Bcdor
`8/1989 M'tsaz'lcuclii ea 3]”
` 2/"1991
`'E'mor<~: (:1; ;{KA
`3'./199}. Longneclcer et al,
`2/1991 B-mior
`1 111991 K-amt.-to et al.
`1/1992 {C‘iausrsne1'e';
`.11./1992 Heltchc
`4/1.993 Claiissiier et 2:}.
`S,’ 1993 Scheffier et MI4
`12/1993 Eleriche
`ll/1994 Stsiclze em!‘
`5/1995 BoiILi'aliR
`37.997 St Th‘-.tal.
`2/1997 mi.
`8/1997 Rainaraj etal.
`1./1998 ‘T}'c«ei:.g em.
`ll./19.‘5'S Sequcira at al.
`.1 21199-3 E_,i~Btwel et a1.
`3/'l999 Sequcira et al.
`6/1999 Otterlt-eck et
`ll)/1999 Seidrll
`“@399 3°90’
`l./.-I000 Alfonso etal.
`5/?.(‘:()0 Scqiieira et 21.
`X‘:l?“_‘4"—t
`1/
`ieaea.
`.7200! Bi
`d‘l<‘. ‘!t’l.
`P1:/2%! Adgéiijlcé all "
`£1‘/'2()0l Modi
`11/299; mbms;
`12/206} }1ei"v‘e et al.
`-1S“Aal];{\:.£"lSl-E{.}f'dIllUJ1(l{il al.
`'2
`_./,
`’-irau eta.
`7/2c-oi Fassberg eta.
`{jhauvin at EL
`{Cmmm55)
`FQR}33lGN }.’ATE.‘:~T DOCl_i’.v£EN"l”S
`2ao3244799
`:2/2003
`(Centinued)
`~.
`-
`.
`—.
`rwry
`:.:-;Ei’£. PUBLl(,ATlUN’:>
`‘
`€)t’s‘ice/action (Final) -Med Feb. 18, 2011 (23 pages), Ll-CS. Appl. No,
`2 ‘5 " :,3ss, £21-rd J 11. ‘*3. 200;:
`I
`/
`(M
`v
`1
`A '
`;
`» 1»
`‘
`i
`(tommual)
`.
`.
`._
`W
`.,
`I._
`i
`V
`1.
`.
`~"’*’j”""/£f““-’f*”'"""f"‘a““ 3&3“
`//lsszslani jsxamnzer
`ll:-.7: Nielsen
`(74) Attorney: Agent, or Firm Conlev Rose. P.C.;Rodi1ey
`3 Cm.m1~g
`"
`'
`1'
`‘
`
`(54) COM}§INA'fi‘iG§Q OF AZELAS'}"L‘QE ANQ
`r- A
`S1 Egflifis
`
`‘
`,
`N
`_
`_
`T
`Inventors: A1313? Liilla, [wombat (13%); {seems
`M alla otras, Bvluxnlcai (IN)
`
`p
`_
`(75)
`
`(73) Assignee: Cl’_'£3l,A Liinitcd, l\/liamlcai (IN;
`
`( "3 ) Notice:
`
`Subject to any disclaimer, the term o1‘tl1i.=;
`
`15_/5,(b\‘, 3., 77 daxis‘
`"
`'
`"
`'
`—
`,
`,
`7,
`-vv
`("U ‘”’*?Pl*"""’“ 3»?/3793:’
`,
`_
`(22)
`369.10, 21310
`(65)
`L§’i'ior l.’uhlia::3tinii Data
`
`fused:
`
`US 2011}/’1)331§:89Al
`
`Dec. 30, 2010
`
`Related U.S.Application Data
`filed as
`(62) Division of application No. 10/518,016,
`application No. PCT/GB03/02557 on Jim; 13, 2003.
`,
`.
`.
`.
`.
`.
`,
`.
`~ -\
`l3‘ei'eigi3 A.}‘l§'.1lj4.‘.ail{‘:K1 Pimority Data
`(31),:
`Jim. 1:-12(24):
`(GB)
`02.13'739.6
`
`,
`
`None
`
`(51)
`
`rs ‘
`V6"
`
`]_nt_(j1_
`-
`-
`A
`(~“'GQ{"m3‘
`A61K31/55
`U.S. CL .....................................................u
`(58) Field of Classification Search
`.
`See application file for complete searcli lijstory.
`.
`'-
`.
`Rem°“‘m °:“t""l
`PAT£<‘N.=“ DOCUME.N'IS
`6/1958 Nobile
`12/1962 Agnello et al.
`et al.
`GY
`I/1971 Voorschoten et al.
`2/1972 Oxley eta].
`8/1973 Ercoli et al.
`8/1974 May etal.
`12/1974 Phillipps et a1.
`6/1975 Pliillipps et al.
`9/1975 Phi11iPPS at 31‘
`ll/1976 Phillipps et al,
`6/1978 Phillipps et al.
`9/ 1978 Kamano et al.
`2/1980 Edwards
`2/1980 Ed
`ds
`4/1980 Alxgéz
`9/1980 Bode, at 31‘
`4/ 1981 Alvaxez
`4/1981 Edwards
`333:;
`1/1982 Edwmds
`6/1982 Phillipps et al.
`3/1983 Stache etal.
`9/1984 Shapiro
`
`
`21%"? 464 A
`2
`°
`.
`3,L6’.7,E.97 A.
`gag $21590
`-1
`3a ‘
`
`A
`3,55‘
`3,639.4..4 A
`3,755,302. A
`3,328,680 A
`3,? 5.323 A
`'
`‘"
`A
`A
`' A
`A
`A
`A.
`A
`4, lgsflm A
`4522£')7g-7 A
`4,261,984 A
`A
`.1 ... 3 1
`4:Z?:5,937 2
`,
`A
`
`'
`.
`1
`A
`4,3:
`.,
`/.3 A
`4,472,393 A
`
`patent is extended or adjusted under 35
`
`i,”~ ,7" ‘.
`r».415,7/43 B1
`
`AU
`
`\
`
`(57)
`
`ABSTRACT
`
`~
`-
`-
`-
`A pharinaceutical product or formulation: which comprises
`azelastine or a pharmaceutically acceptable salt, solvate or
`physiologically functional derivative thereof, anda steroid, or
`a pharmaceutical acceptable salt, solvate or physiologically
`'
`'
`'
`_
`fiinlctiiionalbd.el'1V-3lC1Veftl1CI'C02.E ggrlefgrably S1116 prodiict or for
`11111 a‘ on eing in a orm sui a e or ms or ocu ar admin-
`Islfalloll
`
`28 CE;siIsis,No Drawings
`
`
`
`~wwmmmm~w ‘-'x-'-T-‘M--E-Q-E$x§m¥; g;§K-E ‘ *i véMfififlg' £'g-gigvgy-E§' 7‘;é‘2‘§':i‘g“'*‘““W"-<K'»'~
`
` v.v:v.v.~:-ac-r-:v:v.:~.-.-.-.r.-.-.«,-......... .
`
`
`
`MED_DYM_00018011
`
`

`
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 4 of 40 PageID #: 223
`Case 1:14—cv—01453—LPS Document 43-1 Filed 10/22/15 Page 4 of 40 Page|D #: 223
`
`
`
`I\2
`§_.?E<§ &_§€§3,7§’3 E13
`
`
`WO
`\2Vi.)
`W0
`W0
`We
`W“
`WT‘)
`W0
`W0
`W0
`W,
`W9
`W0
`we
`W0
`We
`we
`We
`W0
`W0
`W5,
`W5,
`W3
`W“
`W“
`M;
`‘W10
`x},/Q
`we
`we
`we
`we
`W0
`W0
`W0
`W0
`we
`
`W0
`
`W0
`.
`'
`
`97402336
`9745243 A1
`93W6..,6
`gmgfi
`98_m.39 M
`990i~,"67
`99,5359
`99;,/W
`00338;;
`003331;,
`00383,;
`604858;,
`0049993
`90555;‘;
`M04138
`;mD3,,,
`0134481
`0154654
`O;5.,025
`Ogsénz
`‘,,;1,m5
`g,;;,,;73g
`0;.',,m’1
`0158745
`Ojéglaé
`95006;;
`0202555
`9397757
`030x243
`5312255
`02.12255
`0213858
`0225723
`0236106
`02053422
`92053135
`02055422
`-7
`1'1’?
`020:/3490
`ggggfigg
`gzfiggjg
`"3
`,
`
`U.S. PATENT DOCUMENTS
`.
`.
`3/2003 B1ggad1ke et :11.
`5/2003 Link etal.
`9/2004 Biggadikeetal.
`7/2005 Cuenoudez 2.1.
`9/2005 Biggadjke 5151.
`7/2007 Pieperetal.
`8/2010 Pairetetal.
`5/2002 Osbakken etal.
`5/2002 Kaplanet 211.
`5/2002 Woolfeetal.
`8/2002 Stacheet a1.
`11/2002 Biggadikeetal.
`11/2002 Biggadjke
`11/2002 Biggadike
`1/2003 Meadeetal.
`4/2003 Biggadikeetal.
`5/2003 Biggadjkeetal.
`7/2003 Biggadike etal.
`8/2003 Cuenoudetal.
`3/2004 Komoto eta].
`7/2004 Garrettetal.
`10/2004 Osbakken et 51.
`11/2004 Weinxichetal.
`12/2004 Yanni et a1.
`7/2005 Miyadiaet 31.
`9/2005 Jost-Price etal.
`2/2006 Lullaetal.
`5/2005 Danget 21.
`10/2005 Lane
`1/2007 Dangetal.
`11/2009 Myles etal.
`11/2009 Lullaetal.
`12/2009 Lullaetal.
`5/2010 Fugeetal.
`
`6,537,983 B1
`5,583,180 B2
`5,787,532 132
`6,921,757 B2
`7,101,855 B2
`7,244,742 B2
`7,775,315 B2
`2002/0061281 A1
`2002/0075382 A1
`2002/0081255 A1
`2002/0103392 A1
`2002/0155211 A1
`2002/0173495 A1
`2002/0177581A1
`2003/0018019 A1
`2003/0073575 A1
`2003/0109511 A1
`2003/0144257 A1
`2003/0158153 A1
`2004/0053904 A1
`2004/0135918 A1
`2004/0204399 A1
`2004/0235807 A1
`2004/0242538 A1
`2005/0163724 Al
`2005/0192261 A1
`_2006/0025391 A1
`2005/0110331 A1
`2005/0228305 A1
`2007/0020330 A1
`2009/0285752 A1
`2009/0291143 A1
`2009/0318397 A1
`2010/0152147 A1
`
`135,
`1319.
`1915
`1319,
`39
`51>
`51*
`
`E9
`B7’
`5?
`111»
`
`93
`GB
`GB
`(533
`63
`GB
`GB
`GB
`GB
`.1»
`I?
`11*
`19
`W70
`W0
`W9
`W0
`we
`W
`we
`we
`W0
`W0
`wo
`we
`we
`
`FOREIGN PATENT DOCUMENTS
`889553 A
`11/1981
`1059905
`5/1959
`3836579 Al
`5/1989
`19947234 A1
`9/1999
`10152359 A1
`5/2002
`°°°4773
`10/1979
`0057401
`8/1982
`0179583
`4/1985
`0393558
`10/1990
`O4 15951
`3/1991
`0780127
`5/1997
`0780127 A1
`5/1997
`1519731 B1
`4/2009
`2072051 Al
`5/2009
`1191955
`57197“
`1296458
`11/1972
`1384372
`2/1975
`1438940
`5/1975
`1517278
`7/1973
`2079755
`1/1982
`2088877
`5/1982
`2140800
`12/1984
`2389530 A
`12/2003
`04208257
`7/1992
`109555
`2/1998
`8291072
`U/1996
`8291073
`11/1995
`2002053485
`2/2002
`8903390
`4/1989
`9015816
`12/1990
`9104252
`4/1991
`9214472
`9/1992
`9531954
`11/1995
`9619199
`6/1996
`9532151
`10/1995
`9701337 A1
`1/1997
`9705136
`2/i997
`9715293
`5/1997
`9721721
`5/1997
`9721724
`5/1997
`9724355
`7/1997
`
`'
`
`W0
`WO
`WO
`W0
`W“
`1761
`W61
`mi,
`gm
`W5
`W0
`.3,”
`0,“;
`V0
`970
`W0
`WO
`W0
`2,,
`"‘
`
`2;.2(,_;',.;
`;,3,§B,j,2.,
`4'/20-713
`03033000
`4.2051
`03035558
`§,m,.,
`M34069 1
`5.200%
`07z;M2.,29
`3'/200%
`03042230
`3/2003
`03048181
`,/200%
`W)6.,,,59
`Ejzcm
`M:,63345
`81.200;
`020660.,’
`8/200%
`0305503};
`?,,;m‘?
`G,,,666‘56
`
`,;,,;(;m
`“‘
`'
`1;,;(;0‘3
`03086 ,,,,
`712/2003
`03105855 A‘
`41,5501
`2(,C_4mg3;36
`’
`,;/5304
`4504910015 A,
`‘1‘,4;,C3
`:;,',?m A‘:
`A’/‘#7’
`‘"1’ '8.,2,,f.Q *1
`~51»
`-~
`~11
`‘
`"
`' ””’
`Ulhbzil UBLIL/i110f\S
`1313355 A5055 (175151) 113155 Feb. 24, 2011 (20 pages), U.S.A;9g3§.1\'o.
`i2,..§,9., £1 M11 .1, W39
`,
`,
`'1
`'.°”“’5
`6
`‘ ‘*’i:“’
`0ffj4'.‘€: Acuzm 11819111 Fan,
`.16, 2011., (22 pages), U3, Apgm. No.
`}O/51870113, filed Jul. -33, 2005,
`/31312591511511 1131.91 Sap. 30, 1010, 1.1.3. Ap}:~l1 No. 12/508,388, /3155
`1111, 23, 2009, 22 pages.
`Office Action dated Sep. 30. 2010, 1.1.3. Azapi. 105. 12/508,393. 5151
`M 73 200,, “page,
`‘
`'
`‘
`,,
`“ _,
`.
`.
`.
`.
`.
`-
`.
`.
`Sch.rmd1.M.W_, T':1e new tog.-1ca1 9,te1'o1d 1-.11.-1esr9111d1: 1s »'—;Lfe>:':1ve 111
`L719 ireairnem of allergic 1313111319," 55111521 of Clinical Phannacologjy,
`1999, m1. 39, pp. 10531059.
`1»1a11:.:.a~5'+‘3x1ai121113, Aug, 2011.
`Mans Ex}1iE:itB, Aug, 201 1,
`
`
`
`,U,.20,,1
`:0‘,2U§,1
`3(,;.2O§,,
`;G‘,.2G:,1
`1,2652
`3,200;
`E/200:1‘
`at/2002
`;/gong
`2/2503
`2/2002
`
`2
`
`V
`4
`
`99"..
`'"""'""'”""""""“"‘
`
`"-*-'-~w-v-wv-----nuzu--1«-1«nu-«nux«-xmm-1“-1-.u1-u~uu-.-u.-.-1-.-1-.-1;-.--1w
`
`
`’.'3.IZVI'.-'.v,"I
`‘"'""""'""'1E?:'§§‘E§Ex7§a3ez1 b§Ti$P?0 ?r23'§§€"iE'§ P5!‘-E3 ‘?£E§'§1?g§2é'§§1“é*Eé§;='?é'25"§E'5?§*?5Y17’é'é37
`. .. .,. ..-.—.v.4~wM~5w wmww.,;.:.,
`
`
`
`
`
`MED_DYM_00018012
`
`

`
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 5 of 40 PageID #: 224
`Case 1:14—cv—01453—LPS Document 43-1 Filed 10/22/15 Page 5 of 40 Page|D #: 224
`
`$,l.é.’§,?I23 32.
`
`
`
`
`
`
`
`
`
`a..
`
`Cll"LA‘ 3 map
`131315 l973l,2t)ll.
`canes can be x'::corrr-
`.
`.<~x.l drug comhinatr
`She
`'11. “J:
`.
`mended?" Currer« l"lr<:rmjieu'ti
`. 1986, pp. .1.
`
`.,
`Opp.'>nr:nt's
`.
`* '=E.P15l. 731, 26-1 1.
`Result of oral prmcszclings dated Oct. :2, 2011 0:1‘ Iii’ Patient
`1519’/f4l.
`
`
`
`
`G'ppm3cnt’s aubmissitin dated Oct. 6, 2011 to J".P}’:~tr:11t.‘w'o 1 5 19733.
`l‘atentec"rs SUl’.}Ll'LlSb'14')l'J dater1,‘"'
`. 5, 2011 to if
`1 I
`‘No.
`“)7” '
`
`
`l’.<zt.:*._nte<-;‘.~: rsubmission detail Sep 9, 201}. 1'c~.garrlin.g list 0f3l.1Cl'1'.":V:.’€.‘>
`at oral ;;ro<.'ecdin;g.=- on El’ Paton
`1 51973 l.
`
`.
`"01 l regarding 13.21‘ of attend-
`
`llclll.
`'1S1-.S1"'/I41.
`ares at oral proceedings on E1’
`‘ep. 13, 20:1 rcgardirigadditional
`0ppor:ent’s 9123.131 slim dai
`'P:1tr:.ui No. 1519731 .
`V
`dated Sega.
`19, 201 l on El‘ Patent 1%.
`
`1, 23. pages, Sclwring
`
`Notice ofAllowance dated Oct. 3, 2011 (33 pages) in U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Salib, et
`211.; “Safety and Tolerability Profiles of Intranasal
`Anihistaminese and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety; 2003; vol. 26, No. 12, pp. 829-911.
`Ofilce Action dated Apr. 7, 201 1 (3 pages) from counterpart applica-
`tion, AU2009243420.
`Product Information, Nasonex®, Aug.
`Corporation, Kenilworth, NJ, US.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC59l-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Product Specification Bulletin, Avicel® CL-611, Bulletin AVC6ll-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Ratner, Paul H., et al., “Combination therapy with azelastine hydro-
`chloride nasal spray and fluticasone propionate nasal spray in the
`treatment of patients with seasonal allergic rhinitis,” Annals of
`Allergy, Asthma & Immunology, Jan. 2008, vol. 100, Cover page,
`publishing page, pp. 74-81.
`Ratner, Paul H., et al., “A Comparison of the Efficacy of Fluticasone
`Propionate Aqueous Nasal Spray and Loratadine, Alone andin Com-
`bination, for the Treatment of Seasonal Allergic Rhinitis,” The Jour-
`nal of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125,
`Appleton & Lange.
`Reddy, Indra K., ed., “Ocular Therapeutics and Drug Delivery: A
`Multi-Disciplinary Approach,” 1996, pp. 382-385 plus cover page
`and publication page, Technornic Publishing Company, Inc.
`Safety Data Sheet. SDS No. 110556, Jul. 4, 2008, V14, Flonase Nasal
`Spray, 5 pages, GlaxoSmithK1ine.
`Safety Data Sheet, SDS No. 110536, Jun. 23, 2008, V13, Beconase
`Hayfever Allergy Spray, 5 pages, GlaxoSmithKli.ne.
`Salib Rami Jean, et al., “Safety and Tolerability Profiles oflntranasal
`Antihistamines and Intranasal Corticosteroids in the Treatment of
`Allergjgic Rhinitis,” Drug Safety 2003, vol. 26, No. 12, Cover page,
`publication page, pp. 863-893, ADIS Data information BV.
`Simpson, Richard J., “Budesonide and terfenadine, separately and in
`combination, in the treatment of hay fever," Annals of Allezgy, Dec.
`1994, vol. 73, Cover page, publication page, pp. 497-502.
`Specter, Sheldon, “Ideal pharmacotherapy for allergic rhinitis,” J
`Allergy Clin Immunol, 1999, Vol. 103, No. 3, Part 2, pp. S3 86-S387,
`Mosby, Inc..
`Wang, De-Yun, “Treatment of Allergic Rhinitis: H1-Antihistamines
`and Intranasal Steroids,” Current Drug Targets—l_nfiammation &
`Allergy, 2002, Vol. I, pp. 215-220, Bentham Science Publishers Ltd.
`Wiseman, Lynda R., et al., "lntzranasal Fluticasone Propionate: A
`Reappeaisal of its Pharmacology and Clinical Efiicacy in the Treat-
`ment of Rhinitis,” Drugs, 1997, vol. 53, No. 5, pp. 885-907, Adis
`International Limited.
`1 Interna-
`World Review 2001: The Pharmaceutical Market, vol.
`tional, IMC Health, 2001, cover, preface, and copyright pages plus
`pp. 4-42 and 5-1 flirough 5-ll, IMS A.G.
`Applicant Response to foreign communication EP Patent 1519731,
`Aug. 11, 2011, 252 pages.
`“Azelastine,” STN Registry No. 58581-89-8, STN Registry File,
`Retrieved Nov. 23, 2010, p. l.
`“Fluticasone Furoste," STN Regislzy No. 397864-44-7, STN Regis-
`try File, Retrieved Nov. 23, 2010, p. l.
`Astepro (azelastine I-ICI) Nasal Spray 0.1 5%, Mecla Pharmaceuticals
`Inc., 2009, Press Release, pp. 1-4.
`Aigbirhio, Franklin 1., et al., “Automated radiosynthesis of n0-ca.r-
`rier—added
`[S—fluoromethyl-18F]Fluticasone
`propionate
`as
`a
`radiotracer for lung deposition studies with PET,” Journal ofLabelled
`Compounds and Radiopharmaceuticals, vol. 39, No. 7, 1997, pp.
`569-584.
`Austin, et a1., “Mometasone furoate is a less specific glucocorticoid
`than fluticasone propionate,” Eur. Respir. J., 2002, vol. 20, pp. 1386-
`1392.
`Bauov, et 211., “Once daily intranasal fluticasone propionate is efi'ec-
`tive for perennial allergic rhinitis," Annals ofAllergy, 1994, Vol. 73,
`pp. 240-246.
`
`Baum;
`n, C,, et a1., “Initial treatment of symptomatic mild to
`moderate bronchial
`asthma with the
`salmeterol/fluticasone
`propionate (50/250pg) combination product (SAS 40023),” Euro-
`pean Journal of Medical Research, 2002, vol. 7, pp. 1-7.
`
` ‘l:3l9’/3.1.
`
`. -
`
`’
`
`E‘atentee’s "response r;f'.‘:?'e:p. 15, 2010 of E1’ Patent 1%.‘.-. 1 51973 1.
`"Ha pal, Frank '12., et al., l')cul;lc—l;1irrr1. placrslrov-controlled study of
`ateiaztine and iluticasone in
`single
`y rlelivexy dwice.
`
`Annals of Allergy. Asthrrla
`lmrmm-.4
`0. 2010, mi. 105, pp
`168-1.73.
`Big;,_>.ariike=,
`lieié, Letter
`to the Editor. “Fluticasone furoatef
`>:k524
`6.
`_ Tmim:-Ll, 2501 1, pp. 183-184.
`
`tjzortt summary Wit}; critical appraisal, lluticaaone
`-
`'
`924. 1
`oate ver s-..4s iluiica souc proplonate for seasonal allergic .1hinil'Es: a
`w of the clinical arid cost.-effectiveness, Jun. 13, 2011.
`
`licasonc llarr-mate for Seasotiai All géc Ellirrilis.
`Dfiicc Actiou {12?9(1S'<7f_.?. 9. .2011 0551] .8. Appl. No. l2/r308.38€<,
`Jul. 23, 2009.
`Otllczé Action dated Sep. 15, 201 1 v.":f"-fJ.S.A;ipl.l‘>Eo. 12r'5(l£<,393, filed
`Jul. 23. 2009.
`Seamh Report dztted May 12, 2009 ofEP (190751 01..
`Search Report dated May 12. 31109 r3.1'E1’ i39C 51119.
`
`
`
`
`
`filed
`
`
`Drugs of the Future, i’r'ous Science, BS,
`'
`..
`1, Nov. 2001, pp lll3.'9~lO3_‘.‘.
`
`
`
`Applicants” response dated Oct.
`12/374 33-,.f1l<tr.1.lsn.. 21, 200.9.
`Clfice Action dated 3‘-lov. 30, 2010 (15 pages), US. App}. No.
`E21374 523, filed Jan. ‘it, 7009.
`.
`' b. 24, (2010) 2011 (3 pages) in US.
`774,523, i.‘-.51:/.l.?ar1.21, 2009.
`-’Finz.l} dated lVl.‘&j-' 3, 201 l (8 pages}, U Appl. No.
`
`'
`331.21, 2(}€}‘.5.
`.
` 201.1 (5? pages) :1“-. 11.8. Appi. Mo.
`respoizsct datetl J‘-an
`..,, filed Jan. 21, 217179.
`e ofNon~r‘ rx>ui;ix'c_/mreudmerrt vfiated .l‘ul. 6, 302 l (3 ;:-ages),
`l\
`L Appl. ‘.\‘o. 12/374.523, filed Jan. 211, 2009.
`.
`response dated Sep. 6, 201 1 (8 pages") in US. Appl. No.
`
`.
`, 23,ii.ic(1.1a::. 21.2009.
`Specter, Sheldon, “Ideal pharmacothcrapy for allergic 1
`
`
`
`Srrcct. “1"he complete rhinitis comroi," 6
`
`l.imited, M=.nul~.-ai, ludia, 21)-T3/-'1.
`n Bulletin, Aviccl-‘R RC-591, liéiilletin AX/C591-
`Protiuct. Sfjecifl
`.
`ages. l7'MC'BioPoly1ue Feb. 2009.
`3 l‘>':':l1etEn, An/i<:e1® (
`Product Spa»;
`1, Bulletin A.‘v't‘.(\.l I,-
`
`SPEfL02!'09.RS, 2, . es, FMC Peiofiolymer, lien. 2009.
`File liisroiy of Braziuan Parer1tA‘pp1lr;ation No. Pl 03121283, 27’
`pages, Apr. 201 1.
`
`1731:: history oftlamidiarr Patent Applicatloaa No. 2,-‘l»>.'<9,42'.v‘, 19 pages,
`
`.Dcc .010
`File history of Polish l’aten1: Applicariott No. Tr‘-3’.'300l. 95 I’3‘e’.e51
`May 201 I.
`
`“=10. RU 3.3615593 C2.
`‘E-‘ii-:2 history -f~Rus.<.i;n.:. P:r.tentApp1icat
`p-.v.gr:s,_«>r;_:-1'. 2009.
`
`
`
`
`
`
`
`2010 (8 pages) in US. Appl. No.
`
`M........................,._.L.L,..
`
`w.
`
`.
`.~.-
`
` nu.............unx-u-_uuaM».u-mx..«.ww.....».-.ww--.u.w.w.,..~..-.-..-.-.««a.«:.-.........
`he $31126 iumgge baiatraae on 03/EW2015
`».»............................................................. ..i.~.-.-.»-.-.-.~.-.~.w.-.~.-.........
`
`ma.‘-.M..M.sM..».....--.-.».-.-,-.»...».~».~.w.«
`
`
`
`MED_DYM_00018013
`
`

`
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 6 of 40 PageID #: 225
`Case 1:14—cv—01453—LPS Document 43-1 Filed 10/22/15 Page 6 of 40 Page|D #: 225
`
`as 8,163,723 ‘a2
`3,
`4
`
`Berstein, et al., “Treatment with intranasal fluticasone propionate
`significantly improves ocular symptons in patients with seasonal
`allergic rhinitis,” Clin. Exp. Allergy, 2004, vol. 34, pp. 952-957.
`Brooks, et al., “Spectrum of seasonal allergic rhinitis symptom relief
`with topical corticoid and oral antihistamine given singly or in com-
`bination,” American Journal of Rhinology, 1996, vol. 10, No. 3, pp.
`193-199.
`Bryson, et al., “lntranasal fluticasone propionate: a review of its
`pharmacodynamic and pharmacokinetic properties, and therapeutic
`potential in allergic rhinitis,” Drugs, 1992, vol. 43, No. 5, pp. 760-
`775.
`Busse, William, et al., “Steroid-sparing effects of fluticasone
`propionate 1001ig and salrneterol 50 pg administered twice daily in a
`single product in patients previously controlled with fluticasone
`propionate 250 pg administered twice daily,” J. Allergy Clin.
`Immunol, vol. 111, No. 1, Jan. 2003, pp. 57-65.
`CAS Registry No. 102113-406, 2004.
`CAS Registry No. 90566-53-3, “Fluticasone,” Nov. 16, 1984.
`Chapman, et al. , “Anti-inflammatory activity of inhaled mometasone
`firroate in allergic mice,” Arzneimettelforschung (“Drug Research”),
`1998, vol. 48, No. 4, pp. 384-391.
`Daley—Yates,
`et al.,
`“Systemic bioavailability of fluticasone
`propionate administered as nasal drops and aqueous nasal spray
`formulations,” Br. J. Clin. Pharmocol, 2001, vol. 51, pp. 103-105.
`Derby, et al., “Risk of cataract among users of intranasal
`corticosteroids,”J. Allergy Clin. Immunol., 2000,vol. 105, No. 5, pp.
`912-916.
`
`Dewester, eta1., “The efiicacy of intranasal fluticasone propionate in
`relief of ocular symptoms associated with seasonal rhinitis,” Allergy
`and Asthma Proc., 2003, vol. 24, No. 5, pp. 331-337.
`Dictionary ofOrganic Compounds, 6th Ed., vol. 1, p. 3234, definition
`of “fluticasone,” Chapman & Hall, 1996.
`Dolovich, et al., “Multicenter trial offluticasone propionate aqueous
`nasal spray in ragweed allergic rhinitis,”Annals ofAllergy, 1994, vol.
`73, No. 2, pp. 147-153.
`Fowler, Stephen J., et al., “Step-down therapy with low-dose
`fluticasone-salmeterol
`combination
`or
`medium-dose
`hydrofluoroalkane 134a-beclomethasone alone,” J. Allergy Clin.
`Immunol., vol. 109, No. 6, Jun. 2002, pp. 929-935.
`Garner, R. C., et al., “A validation study comparing accelerator MS
`and liquid scintillation counting for analysis of 14C-labelled drugs in
`plasma, urine and faecal extracts,” Journal of Pharmaceutical and
`Biomedical Analysis, vol. 24, 2000, pp. 197-209.
`Gawchik, et al., “Comparison of intranasal triarncinolone acetonide
`with oral loratarline in the treatment of seasonal ragweed-induced
`allergic rhinitis,” Am. J. Man. Care, 1997, vol. 3, No. 7, pp. 1052-
`1058.
`
`Harding, “The human pharmacology offluticasonepropionate,” Res-
`piratory Medicine, 1990, vol. 84, Suppl. A, pp. 25-29.
`Howland, “Fluticasone propionate:
`topical or systemic effects?”
`Clinical and Experimental Allergy, 1996,vo1. 26, Suppl. 3, pp. 18-22.
`Isogai, et al., “Binding affinities ofmometasone furoate and related
`compounds including its metabolites for the glucocorticoid receptor
`ofrat skin tissue,” J. Steroid Biochem. Mol. Biol., 1993, vol. 44, pp.
`141 -145 .
`Johansson, Gunnar, et al., “Comparison of salmeterol/fluticasone
`propionate combination with budesonide in patients with mild-to-
`moderate asthma," Clin. Drug Invest., vol. 21, No. 9, 2001, pp.
`633-642, 11 pages.
`Juniper, Elizabeth F., et al., “Impact ofinhaled salrneterol/fluticasone
`propionate combination product versus budesonide on the health-
`related quality of life ofpatients with asthma,” Am. J. Respir. Med.,
`vol. 1, No. 6, 2002, pp. 435440.
`Kenley, Richard A., et al., “An automated, column-switching HPLC
`method for analyzing active and excipient materials in both cream
`and ointment formulations,” Drug Development and Industrial Phar-
`macy, vol. 11 (9 & 10), 1985, pp. 1781-1796.
`Kertesz, Denis J., et al., “Thiol esters from steroid 17B-carboxylic
`acids: carboxylate activation and internal participation by 17
`oi-acylates," J. Org. Chem., vol. 51, 1986, 14 pages.
`Kooreman, eta.1., “The synthesis of 17-esters of corticosteroids pro-
`tection of 1l[5~hydroxyl ofthe trimetlrylsilyl group,” Synthetic Com-
`munications, vol. 1, No. 2, pp. 81-87, 1971.
`
`Laforce, etal., “Fluticasone propionate: an effective alternative treat-
`ment for seasonal allergic rhinitis in adults and adolescents,” J. Fam.
`Pract., 1994, vol. 38, No. 2, pp. 145-152.
`new capillary
`a
`of
`Lane,
`S.
`J.,
`et
`al.,
`“Evaluation
`electrochromatography/mass spectrometry interface using short col-
`umns and high field strengths for rapid and efficient analyses,” Rapid
`Communications in Mass Spectrometry, vol. 10, 1996, pp. 733-736.
`Lewis, Sarah A., et al., “Association of specific allergen sensitization
`with socioeconomic factors and allergic disease in a population of
`Boston women,” J. Allergy Clin. 1.mmu.no1., vol. 107, No. 4, Apr.
`2001, pp. 615-622.
`Li, et al., “Synthesis of aryl 5-(2-chlorophenyl)-2-fiiroates under
`phase transfer catalysis,”Synthetic Communications, vol. 32, No. 20,
`pp. 3081-3086, 2002.
`Linder, “Symptom scores as measurements of the rsevcsritjy -:«f
`rhinitis,” Clinical Allergy, 1988, vol. 18, pp. 29-37.
`Lutsky,
`al., “A novel class of potent topical antiinflammatory
`agents: 17-benzolyated, 7a-halogeno substituted corticosteroids,"
`Arzneimettelforschung (“Drug Research”), 1978, vol. 29, No. 1 l , pp.
`1662-1667.
`Lyseng-Williamson, Katherine A., et al., “Inhaled salmeterol/
`fluticasone propionate combination in chronic obstructive pulmo-
`nary disease,” Am. J. Respir. Med., vol. 1, No.4, 2002, pp. 273-282.
`Mahoney, Janette M., et al., “Drug effects on the noovascularization
`response to silver nitrate cauterization ofthe rat cornea.” Current Eye
`Research, Vol.4, No.5, 1985, pp. 531-535.
`Millard, Jeffrey W., et al., “Solubilization by cosolvents establishing
`useful constants for
`the log-linear model,” Int’l
`Journal of
`Pharrneceutics, vol. 245, 2002, pp. 153-166.
`Mistry, Nisha, et al., “Characterisation of impurities in bulk drug
`batches of fluticasone propionate using directly coupled HPLC-
`NMR spectroscopy and HPLC-MS,” Journal of Pharmaceutical and
`Biomedical Analysis, vol. 16, 1997, pp. 697-705.
`Mistry, Nisha, et al., “Impurity profiling in bulk pharmaceutical
`batches using 19F NMR spectroscopy and distinction between
`monomeric and dimeric impurities by NMR-based diffusion mea-
`surements,” Journal ofPharmaceutical and Biomedical Analysis, vol.
`19, 1999, pp. 511-517.
`,
`Moreno-Vargas, et al., “Synthesis and gylcosidase inhibitory activi-
`ties of 5-(1‘,4'-d.ideoxy-1',4'-imino-D-erythrosyl)-2-methyl-3-furoic
`acid (=5-[(3S,4R)-3,4-dihydroxypyrrolidin-2-yl]-Zmethylfuran-3-
`carboxylic acid) derivatives: new leads as selective alpha-L-
`fucosidase and beta-galactosidase inhibitors,” Helvetica Chimica
`Acta, vol. 86, pp. 1894-1913, 2003.
`Nathan, et al., “A once daily fluticasone proprionate aqueous nasal
`spray is an effective treatment for seasonal allergic rhinitis,” Annals
`ofAl1ergy, 1991, vol. 67, pp. 332-338.
`Nelson, Harold, S., et al., Fluticasone propionate-salmeterol combi-
`nation provides more effective asthma control than low-dose inhaled
`corticosteroid plus montelukast, J. Allergy Clin. Immunol., vol. 106,
`No. 6, Dec. 2000, pp. 1088-1095.
`Ong, John T. H., et al., “Micellar solubilization oftimobesone acetate
`in aqueous and aqueous propylene glycol solutions of nonionic
`surfactants,” Pharmaceutical Research, vol. 5, No. 11, 1988, pp.
`704-708.
`Ong, John T. H., et al., “Intrinsic potencies of novel thiol ester
`corticosteroids RS-85095 and RS-213 14
`as compared with
`clobetasol 17-propionate and fluocinonide,” Arch Dermatol, vol.
`125, Dec. 1989, pp. 1662-1665.
`Oniust, et al., “Mometasone furoate, a review ofits intranasal use in
`allergic rhinitis,” Drugs, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol.
`2 l .
`
`Pettersson, Bertil, et al., “Re-evaluation ofthe classical mycoplasma
`lipophilum cluster (Weisburg, et al., 1989) and description of two
`new clusters in the hominis group based on 16S rDNA sequences,"
`Int’l Journal of Systematic & Evolutionary Microbiology, 2001, vol.
`51, pp. 633-643.
`Phillips, G. H., et al., “Synthesis and structure activity relationships
`in a series ofanti-inflannnatory corticosteroid analogues, halomethyl
`androstane—I7B-carbothioates a.nd—l7B-carboselenoates,” Jour-
`nal ofMedicinal Chemistry, 1994, vol. 37, pp. 3717-3729.
`Product Information Flonase (Fluticasone proprionate) Nasal Spray
`50 mcg, 2004, pp. 1-13.
`
`w.M.~u.\-vu--u---v~....
`-an-vaaos-vvrnmt-x-...s-1-in-tn
`
`by USPTO irom the PIRS Image Database on 03/04/2015
`,-.-,-,-.-,-.~:~'.v.»:v,v.v.a,-a-,-.-.-,».»-.-.-......
`
`
`
`n---rm-.\..-.»...«.v...,.....-,4-.-.-.-...-.-.-..:.~.-.~¢vw.-mwaa....--.-‘wt-.(-.-.-.-.-1-.-.-.
`
`..................................................... .
`
`.
`
`MED_DYM_00018014
`
`

`
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 7 of 40 PageID #: 226
`Case 1:14-cv-01453-LPS Document 43-1 Filed 10/22/15 Page 7 of 40 Page|D #: 226
`
`if’; 3,163,723 $2
`.{’a_r:c 3
`
`
`
`lat’!
`
`rvations on p eiitalwility of me -;-inject c1':l:.c pzttzmr. appli1;-ation
`3-352 (Lze-cit Republic), 7003.
`‘
`No cc ofO;,.v;gc-sition to the gran t r.‘:'fpa1e:r.t on P:i.tr:nt :51;-plica.tiorr No.
`762/?’ G}. (_14(‘.~39’."l (_l?akisLin). ‘.3010.
`if1':-sport shows that Ll‘-.cy
`CIPLA Aruruai 1’-.c:pmt Extract; 21010;
`tauxuclrrsd an F9 zeiastirie produc. in 10).
`fir: ’
`tic:-Ii oft"
`‘~'na M:-tlhctra for l:'LPi5l 9731 dater_i.—’s11g. 11, 20.1.1.
`
`
`
`7
`azaori of Jca-zhim l‘v’l!t\lS- .='.'=_n P15 19731 dated Au->.
`"
`
`
`it-“J~).t1‘.’€.’:~
`"-'
`in ophthalmic formuiatiomz
`p. Oftalmol, 2'Z)0'.I',v-7.-l. 81. pp. 531-532.
`'
`.V.'l'iihit A. Aug.
`1..
`M.il’-
`
`eet CO11\})€Xl(lii.lfr1, 11995-96, cover ‘;«age plus pp. 3 3-39,
`A81’
`rrbiic ‘to. Lirrtited, Lon-71-:-rs. (iota). Britain.
`Akeriuxrd, !~‘tuders
`. “(.'linicaE tr
`
`.
`
`
`
`
`
`
`
`
`
`A'«ir;ol® ' VCL, 1‘./Ii-:ro«:i'ystaliir:.e ffellulose. and 4CarborqIrriethylccl-
`intone $.;.rl:s‘:m, J13 Dispe ‘ible Celltalose, HP, Spe<;if_5.cation=.: prlti.
`Analytical Metlrocis. E.(‘.~l6 Updated Oct‘. 1995 (Feta. 1.999‘), 6 pages.
`FEVIC
`1
`‘mar.
`
`Oppositirarr to F1‘ 15 >I<’I’3l, Aug. 8, ‘.201 1., E9 gragxs.
`
`Aurora, .‘.-‘act’, “l\'
`i Ttklivczry; Devel me-ur oi’Nasal Delivery .‘:‘vys«
`tems: /31 Rex/iev2," Drug Delivery Tet"
`. '1', Get. 2002,
`S giages. http:.€'\vvv"v2.d1u,<gdeiively"
`;en‘ssI'l"Lii3ii-:a-
`tiorts: Aiticleé’ ‘
`.13 IF
`‘ 1473? l4fSé'_‘Y A.
`.
`
`Baena-Cagnzu
`‘
`.., “Safety and’
`lerability oi"l”;ea‘rrrxen1:: for
`Allergic Rhrraa
`,hildren," Drug ‘S
`v 21)-314. vol. 2'7, N»:-. 12, pp.
`333-898, ALFES D
`Information i.&‘.i.
`Barnes, M. 1..., et .31., "‘.-'~lfi'-.-rots; of ‘:evo»'.-etirizine 18 {add-or: ’t‘l~.crm;.vy to
`
`fliiricasom: in sea
`nal allergic r’tiiuitis,”
`
`
`
`Block, John EL,
`
`Indian Edition, ‘v’srg.h<'=se £‘ia3:x
`_
`Cipla Sixt);-Ninilr Arxrmsl Report 2004-
`.3, 5, ‘ind 44.
`., “l?.:zndomi
`st.-no aqu».~.m.1rs nasal st:
`}3ELYiE,_.,
`
`plus csatirizine. fiuticascne
`rrtonreiuicast for
`vol. 34, pp.
`
`
`
`, cover pages, im°orma-
`
`.
`
`
`
`l’1ar‘.:-:?;o-controllr:d Trial 1.
`'
`rlierapy, fiul.lC3..\ net
`
`
`
`
`
`
`
` E
`
`.
`Pile iristory of Brazilian Patent" Application "No. H 03E? 128-3, 2.7
`
`pay <.
`File liistury Canadian Patent Ap;;rl§cario.u No
`File history; oriléorean E-‘a1er5tApplic.a.t'ron No. If
`pages.
`File his:-::«3y of lvlexic-an Patent A_pp‘:icar.io.11 No. l’r’t-':'n';.(‘?tl>1.'t)!2(’;r3
`(now Pnierrt No. 265 .7-4'9). 36 par.
`
`
`File‘. ixa-;l'0r)' of Poiish Patent Ag ,,
`~ ‘Jo. P-373002 95 pap," .
`Fiie hi::t<>ry of Russian. Patent App;
`rcation No. RU 2351593 (Iii, 65
`pages.
`
`
`
`
` xuu-‘K
`-wmmm».w«.~.a.-;.:.~.-.~.~«.-.-wv-vw«----av-*----.-r--M-r-.-.-.-.-A-w.......,..................r-.-run.»-’I'I"’V"""""""V"""V’V'-‘---x-.-\~Iv«-vv4..-..............ra-.....o.».-.~M«~.
`-.....»,-.............“.“.,...............-M-t.......~.».»...».~.».-w-.m.«-r.-.-.-.-.-.~.
`
`Copy provided by USSPTO from the £9323 mange Database on {bit/04/2£3i5
`
`
`
`
`
`MED_DYM_00018015
`
` polypo.
`
`cozuiruu .ir;ation«~--KREG--2004-
`
`
`
`Li rlifteent classes of rricdiv:
`’.ZG05, voi. 1,
`lmm:;nol., Ni:
`- gin
`zktigviicants
`.1‘. grease to E-:-re
`7020819, Dec 7"
`, 31011), 13 pages.
`:0 ‘l‘o1'r‘.ig.n r:or:rrmmicaiion~---E"? 03738280.}.
`
`Product Information Rhinocort Aqua (hudesonide) Nasal Spray 32
`mcg, 2005, pp. 1-2.
`Sakagami, et al., “Mucoadhexive BDP rnicrospheres for powder
`inhalation—t_hei.r unique pharmacokinetic-pharmacodynamic pro-
`files,” Respiratory Drug Delivery, vol. VI, pp. 193-199, 1998.
`Sarrdha.m, et al., “Synthesis and biological properties of novel
`glucocorticoid androstene C-17 furoate esters,” Bioorganic &
`Medicinal Chemistry, 2004, vol. 12, pp. 5213-5224.
`Scadding, et al., “Clinical and physiological etfects of fluticasone
`propionate aqueous nasal spray in the treatment ofperennial rhinitis,”
`Rhinology, 1991, Suppl. 11, pp. 37-43.
`Settipane, et al., “Triamcinolone acetonide aqueous nasal spray in
`patients with seasonal ragweed allergic rhinitis: aplacebo-controlled,
`double-blind study,” Clin. Ther., 1995, vol. 17, No. 2, pp. 252-263.
`Shapiro, et al., “17-esters and 17,21-diesters of 9-alpha, ll-beta-
`dichlorocorticoids. Synthesis and anti-inflarrrmatory activity,” Ste-
`roids, vol. 9, No. 2, pp. 143-156, 1967.
`Shapiro, et al., “Synthesis and structure-activity studies of
`corticosteroid 17-heterocyclic aromatic csters. 1. 9-alpha, ll-beta
`dichloro series,” Journal of Medicinal Chemistry, Vol.30, No. 6, pp.
`1068-1073, 1987.
`Shapiro, et al., “17 heteroaroyl esters of corticosteroids 2. 11 beta
`hydroxy series,” Journal of Medicinal Clrernistry, American Chemi-
`cal Society, Washington, US, vol. 30, No. 9, 1987, pp. 1581-1588.
`Smith, et al., “In vitro glucocorticoid receptor binding and transcrip-
`tional
`activiation
`by
`topically
`active
`glucocorticoids,”
`Arzneimettelforschung, 1998, 48(II)(9), pp. 956-959.
`Smith, N., et al., “Comparison ofthe electroosmotic flow profiles and
`selectivity
`of
`stationary
`phases
`used
`in
`capillary
`electrochromatography,” Journal of Chromatography A., vol. 832,
`1999, pp. 41-54.
`Souness, et al., “Immunosuppressive and anti-inflammatory effects
`of cyclic AMP phosphodiesterase (PDE)
`type 4 inhibitors,”
`Irnmunopharrnacology, 2000, vol. 47, Nos. 2/3, pp. 127-162.
`Stempel, et al., “Treannent of allergic rhinitis: an evidence-based
`evaluation of nasal corticosteroids versus nonsedating antihista-
`mines,” Am. J. Man. Care, 1998, vol. 4, pp. 89-96.
`Study No. 03DMW062—“Pharmacokinetics of GW685698X and
`CC11878l (fluticasone propionate) when co-administered by the
`intratracheal or intravenous route to the anaesthetised white pig,”
`2004.
`Study No. B30947——“The Pharmacokinetics of GW685698X and
`CC1 131381
`following intratracheal
`co-adrninistration to
`the
`anaesthetised white pig,” 2003.
`Szefler, Stanley J., et al., Chapter 21, “Glucocorticoids in severe
`asthma: mechanisms ofaction and route ofad.mi.nistration,” Difficult
`Asthma, pp. 371-375, 3‘«§.ari_iu Dunitz Ltd., Infomta Health Care,
`1999.
`Togashr, et al., 9-fluoro-11B, 17, 21-trihyrdroxy-16a-methyl-1